Sorry, that's a little hard to read. I'll bold it instead.
Aluminium hydroxide (AH) and aluminium phosphate (AP) adjuvants, labelled with 26Al, were injected intramuscularly (i.m.) in New Zealand White rabbits. Blood and urine samples were collected for 28 days and analysed for 26Al using accelerator mass spectrometry to determine the absorption and elimination of AH and AP adjuvants.
So this part is pretty self-explanatory. They infected two different aluminium salts (AH and AP) intramuscularly into some rabbits. One group of rabbits were injected with AH, the other group with AP. They took blood and urine samples from each rabbit for 28 days and looked how much aluminium was present in them.
26Al was present in the first blood sample (1 h) for both adjuvants.
After one hour aluminium was present in the blood for both the AH and AP group.
The area under the blood level curve for 28 days indicates that three times more aluminium was absorbed from AP adjuvant than AH adjuvant.
When injecting AP more aluminium is absorbed than when injecting AH. This is important because it shows that the two salts are handled differently by the body.
The distribution profile of aluminium to tissues was the same for both adjuvants (kidney > spleen > liver > heart > lymph node > brain).
So, with both salts the aluminium was distributed in the same places. The most was found in the kidneys, less in the spleen, then the liver, then heart, lymph nodes and then the least aluminium was found in the brain.
This study has demonstrated that in vivo mechanisms are available to eliminate aluminium-containing adjuvants after i.m. administration. In addition, the pharmacokinetic profiles of AH and AP adjuvants are different.
This just summarises the study. It's saying that there are bodily mechanisms present that can remove aluminium after injecting it into the muscle. The body also deals with AH and AP differently.